DOCSLIB.ORG

Natural Products

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Natural Products Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com Natural Products www.MedChemExpress.com 1 Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com Target List in Natural Products • Saccharides and Glycosides 3 • Phenylpropanoids 14 • Quinones 24 • Flavonoids 28 • Terpenoids and Glycosides 47 • Steroids 69 • Alkaloid 79 • Phenols 104 • Acids and Aldehydes 113 • Others 134 2 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Saccharides and Glycosides Saccharide is also called carbohydrate, consisting of carbon (C), hydrogen (H) and oxygen (O) atoms, usually with the empirical formula Cm(H2O)n. The saccharides are divided into four chemical groups: monosaccharides, disaccharides, oligosaccharides, and polysaccharides. Carbohydrates perform numerous roles in living organisms. Polysaccharides serve for the storage of energy (e.g. starch and glycogen) and as structural components. The 5-carbon monosaccharide ribose is an important component of coenzymes (e.g. ATP, FAD and NAD) and the backbone of the genetic molecule known as RNA. The related deoxyribose is a component of DNA. Saccharides and their derivatives include many other important biomolecules that play key roles in the immune system, fertilization, preventing pathogenesis, blood clotting, and development. A glycoside is a molecule in which a sugar is bound to another functional group via a glycosidic bond. Glycosides play numerous important roles in living organisms. Many plants store chemicals in the form of inactive glycosides. These can be activated by enzyme hydrolysis, which causes the sugar part to be broken off, making the chemical available for use. Many such plant glycosides are used as medications. In animals and humans, poisons are often bound to sugar molecules as part of their elimination from the body. www.MedChemExpress.com 3 Saccharides and Glycosides Inhibitors & Modulators 1-Kestose 1F-Fructofuranosylnystose Cat. No.: HY-N2579 Cat. No.: HY-N2577 Bioactivity: 1-Kestose, the smallest fructooligosaccharide component, which Bioactivity: 1F-Fructofuranosylnystose can be used in the synthesis of efficiently stimulates Faecalibacterium prausnitzii as well Fructooligosaccharides (FOSs). Fructooligosaccharides exhibit as Bifidobacteria. lots of beneficial effects on our health and have been used as food ingredients. Purity: 99.01% Purity: 99.87% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 5 mg 10 mg, 25 mg 2'-Deoxycytidine (Cytosine deoxyribonucleoside; Cytosine 2'-Deoxyguanosine deoxyriboside; Deoxycytidine; Deoxyribose cytidine) Cat. No.: HY-D0184 (Deoxyguanosine; Guanine deoxyriboside) Cat. No.: HY-17563 Bioactivity: 2'-Deoxycytidine, a deoxyribonucleoside, could inhibit Bioactivity: Deoxyguanosine(2'-Deoxyguanosine) is composed of the purine biological effects of Bromodeoxyuridine (Brdu). nucleoside guanine linked by its N9 nitrogen to the C1 carbon of deoxyribose. Purity: 97.76% Purity: 99.71% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 100 mg 1 g, 5 g 2'-Deoxyinosine 2'-Deoxyuridine Cat. No.: HY-W008638 Cat. No.: HY-D0186 Bioactivity: 2’-deoxyadenosine inhibits the growth of human colon-carcinoma Bioactivity: 2'-Deoxyuridine could increase chromosome breakage and results cell lines and is found to be associated with purine in a decreased thymidylate synthetase activity. A known use of nucleoside phosphorylase (PNP) deficiency. 2'-Deoxyuridine is as a precursor in the synthesis of Edoxudine. Purity: >98% Purity: 97.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 100 mg 100 mg 2,3,5,4'-Tetrahydroxystilbene 2-O-β-D-glucoside 2-(Methylamino)-1H-purin-6(7H)-one (2,3,4',5-Tetrahydroxystilbene 2-O-D-glucoside) Cat. No.: HY-N0652 (N2-methylguanine) Cat. No.: HY-101412 Bioactivity: 2,3,4',5-tetrahydroxystilbene 2-O-D-glucoside isolats from the Bioactivity: 2-(Methylamino)-1H-purin-6(7H)-one (N2-Methylguanine) is a roots of Polygonum species, inhibits the formation of 5-HETE, modified nucleoside. 2-(Methylamino)-1H-purin-6(7H)-one is an HHT and thromboxane B2, although less strongly. [1] endogenous methylated nucleoside found in human fluids. Purity: 98.72% Purity: 98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 5 mg, 10 mg, 50 mg, 100 mg 10 mg, 25 mg, 50 mg 3-Indoleacetic acid 3-Indolepropionic acid (Indole-3-acetic acid; 3-IAA) Cat. No.: HY-18569 Cat. No.: HY-W015229 Bioactivity: Indole-3-acetic acid (3-Indoleacetic acid; IAA) is the most Bioactivity: 3-Indolepropionic acid is shown to be a powerful antioxidant common natural plant growth hormone of the auxin class. It can and has potential in the treatment for Alzheimer’s disease. be added to cell culture medium to induce plant cell elongation and division. Purity: 99.74% Purity: 98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 g 1 g 4 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] 3-Methylxanthine 6-Biopterin Cat. No.: HY-50723 (L-Biopterin) Cat. No.: HY-102015 Bioactivity: 3-Methylxanthine, a xanthine derivative, is a cyclic guanosine Bioactivity: 6-Biopterin (L-Biopterin), a pterin derivative, is a NO monophosphate (GMP) inhibitor, with an IC50 of 920 μM on synthase cofactor. guinea-pig isolated trachealis muscle. Purity: 97.0% Purity: 98.02% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 100 mg 5 mg, 10 mg, 25 mg, 50 mg, 100 mg 7-Methylxanthine Acarbose Cat. No.: HY-W017163 (BAY g 5421) Cat. No.: HY-B0089 Bioactivity: 7-Methylxanthine, a methyl derivative of xanthine, is one of Bioactivity: Acarbose is an inhibitor of alpha glucosidase, an the purine components in urinary calculi. anti-diabetic drug. Purity: 99.0% Purity: 98.0% Clinical Data: No Development Reported Clinical Data: Launched Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in Water, 50 mg 200 mg, 1 g Acarbose sulfate Acetyl Perisesaccharide C (Bay-g 5421 sulfate) Cat. No.: HY-B0089A Cat. No.: HY-N4222 Bioactivity: Acarbose sulfate is an inhibitor of alpha glucosidase, an Bioactivity: Acetyl Perisesaccharide C is an oligosaccharide, which is anti-diabetic drug. isolated from the root barks of Periploca sepium. Purity: >98% Purity: 98.99% Clinical Data: Launched Clinical Data: No Development Reported Size: 200 mg, 1 g Size: 10mM x 1mL in DMSO, 5 mg Adenine Adenosine (6-Aminopurine; Vitamin B4) Cat. No.: HY-B0152 (Adenine riboside; D-Adenosine) Cat. No.: HY-B0228 Bioactivity: Adenine is a purine derivative and a nucleobase with a variety Bioactivity: Adenosine is a nucleoside composed of a molecule of adenine of roles in biochemistry. Target: Nucleoside attached to a ribose sugar molecule (ribofuranose) moiety via antimetabolite/analog Adenine is a nucleobase with a variety a β-N9-glycosidic bond. Target: Nucleoside of roles in biochemistry including cellular respiration, in antimetabolite/analog Adenosine plays an important role in the form of both the energy-rich adenosine triphosphate (ATP)… biochemical processes, such as energy transfer — as adenosine… Purity: 98.76% Purity: 99.84% Clinical Data: Launched Clinical Data: Launched Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 g, 5 g 1 g, 5 g Allopurinol riboside Amygdalin Cat. No.: HY-101397 Cat. No.: HY-N0190 Bioactivity: Allopurinol riboside, a metabolite of allopurinol, shows Bioactivity: Amygdalin is a plant glucoside isolated from the stones of potent activities against parasites. rosaceous fruits, such as apricots, peaches, almond, cherries, and plums. Purity: 99.04% Purity: 98.03% Clinical Data: No Development Reported Clinical Data: Launched Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 5 mg 50 mg, 100 mg, 200 mg www.MedChemExpress.com 5 Anemarrhenasaponin I Astragalus polysaccharide Cat. No.: HY-N4213 (Astragalus Polysacharin) Cat. No.: HY-N0937 Bioactivity: Anemarrhenasaponin I, a traditional Chinese medicine, is Bioactivity: Astragalus polysaccharide are active components of the isolated from Anemarrhena asphodeloides Bunge. polysaccharides extract of Astragulus, attenuates TNF-α-induced insulin resistance by suppressing miR-721 and activating PPAR-γ and PI3K/Akt in 3T3-L1 adipocytes. Purity: 99.43% Purity: 98.0% Clinical Data: No Development Reported Clinical Data: Phase 4 Size: 10mM x 1mL in DMSO, Size: 50 mg 5 mg Aurothioglucose Betanin (Gold thioglucose) Cat. No.: HY-A0068 Cat. No.: HY-112578 Bioactivity: Aurothioglucose (Gold thioglucose) is a well known active-site Bioactivity: Betanin has potent antioxidant and anti-inflammatory effect, inhibitor of TrxR1, inhibited TrxR1 activity in HeLa cell - that could inhibit peroxynitrite (ONOO ), with an IC50 of cytosol but had no effect on the viability of the cells. 19.2 μM. Betanin is a red glycoside obtained from beets that can be used as colorant. Purity: Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 1 g 5 mg, 10 mg cAMP (Adenosine 3',5'-cyclophosphate; Cyclic Casanthranol 3',5'-monophosphate adenosine; Cyclic AMP) Cat. No.: HY-B1511 Cat. No.: HY-B2134 Bioactivity: cAMP is a mitogenic messenger and promotes the G 1 to S phase Bioactivity: Casanthranol is a concentrated mixture of anthranol glycosides transition
Load more

Recommended publications
  • Bufadienolides from the Skin Secretions of the Neotropical Toad Rhinella Alata (Anura: Bufonidae): Antiprotozoal Activity Against Trypanosoma Cruzi
    molecules Article Bufadienolides from the Skin Secretions of the Neotropical Toad Rhinella alata (Anura: Bufonidae): Antiprotozoal Activity against Trypanosoma cruzi Candelario Rodriguez 1,2,3 , Roberto Ibáñez 4 , Luis Mojica 5, Michelle Ng 6, Carmenza Spadafora 6 , Armando A. Durant-Archibold 1,3,* and Marcelino Gutiérrez 1,* 1 Centro de Biodiversidad y Descubrimiento de Drogas, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT AIP), Apartado 0843-01103, Panama; [email protected] 2 Department of Biotechnology, Acharya Nagarjuna University, Nagarjuna Nagar, Guntur 522510, India 3 Departamento de Bioquímica, Facultad de Ciencias Naturales, Exactas y Tecnología, Universidad de Panamá, Apartado 0824-03366, Panama 4 Smithsonian Tropical Research Institute (STRI), Balboa, Ancon P.O. Box 0843-03092, Panama; [email protected] 5 Centro Nacional de Metrología de Panamá (CENAMEP AIP), Apartado 0843-01353, Panama; [email protected] 6 Centro de Biología Celular y Molecular de Enfermedades, INDICASAT AIP, Apartado 0843-01103, Panama; [email protected] (M.N.); [email protected] (C.S.) * Correspondence: [email protected] (A.A.D.-A.); [email protected] (M.G.) Abstract: Toads in the family Bufonidae contain bufadienolides in their venom, which are charac- Citation: Rodriguez, C.; Ibáñez, R.; terized by their chemical diversity and high pharmacological potential. American trypanosomiasis Mojica, L.; Ng, M.; Spadafora, C.; is a neglected disease that affects an estimated 8 million people in tropical and subtropical coun- Durant-Archibold, A.A.; Gutiérrez, M. tries. In this research, we investigated the chemical composition and antitrypanosomal activity Bufadienolides from the Skin of toad venom from Rhinella alata collected in Panama.
    [Show full text]
  • Diabetic Neuropathy)
    A PROSPECTIVE OPEN LABELLED NON RANDOMIZED PHASE-II CLINICAL TRIAL OF “KADUKKAI CHOORANAM FOR “AKKINI SELATHUMAM” (DIABETIC NEUROPATHY) Dissertation submitted to THE TAMILNADU DR. MGR. MEDICAL UNIVERSITY CHENNAI-32 For the partial fulfillment of the requirements to the Degree of DOCTOR OF MEDICINE (SIDDHA) BRANCH-I DEPARTMENT OF POTHU MARUTHUVAM DEPARTMENT OF POTHU MARUTHUVAM GOVERNMENT SIDDHA MEDICAL COLLEGE PALAYAMKOTTAI - 627 002 TAMIL NADU, INDIA. OCTOBER 2019 GOVERNMENT SIDDHA MEDICAL COLLEGE PALAYAMKOTTAI - 627 002 TAMIL NADU, INDIA. BONAFIDE CERTIFICATE This is to certify that the dissertation entitled “A PROSPECTIVE OPEN LABELLED NON RANDOMIZED PHASE-II CLINICAL TRIAL OF “KADUKKAI CHOORANAM FOR AKKINI SELATHUMAM (DIABETIC NEUROPATHY)” is abonafide work done by Dr.RAJENDRAM AJANTHAN (Reg. No.321611008) Govt. Siddha Medical College, Palayamkottai - 627 002 in partial fulfilment of the university rules and regulations for award for MD (S) POTHU MARUTHUVAM (BRANCH-I) under my guidance and supervision during the academic year OCTOBER 2016-2019. Supervisor and Guide Prof. Dr.A.MANOHARAN, MD (S),( Ph.D). Head, Department of PothuMaruthuvam, Govt. Siddha Medical College, Palayamkottai. Name and signature of the HOD Name and signature of the Principal Prof. Dr. A.MANOHARAN, MD (S),( Ph.D). Prof. Dr.S.Victoria,MD(S) Dept. of PothuMaruthuvam, Govt. Siddha Medical College Govt. Siddha Medical College, Palayamkottai. Palayamkottai. GOVERNMENT SIDDHA MEDICAL COLLEGE PALAYAMKOTTAI - 627 002 TAMIL NADU, INDIA. CERTIFICATE Certified that I have gone through the dissertation entitled “A PROSPECTIVE OPEN LABELLED NON RANDOMIZED PHASE-II CLINICAL TRIAL OF “KADUKKAI CHOORANAM FOR AKKINI SELATHUMAM (DIABETIC NEUROPATHY)” submitted by Dr.RAJENDRAM AJANTHAN (Reg. No.321611008) a student of final year MD(S) Department of Pothu Maruthuvam (Branch-I)of this college and the dissertation work has been carried out by the individual only.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.421,180 B2 Zielinski Et Al
    USOO9421 180B2 (12) United States Patent (10) Patent No.: US 9.421,180 B2 Zielinski et al. (45) Date of Patent: Aug. 23, 2016 (54) ANTIOXIDANT COMPOSITIONS FOR 6,203,817 B1 3/2001 Cormier et al. .............. 424/464 TREATMENT OF INFLAMMATION OR 6,323,232 B1 1 1/2001 Keet al. ............ ... 514,408 6,521,668 B2 2/2003 Anderson et al. ..... 514f679 OXIDATIVE DAMAGE 6,572,882 B1 6/2003 Vercauteren et al. ........ 424/451 6,805,873 B2 10/2004 Gaudout et al. ....... ... 424/401 (71) Applicant: Perio Sciences, LLC, Dallas, TX (US) 7,041,322 B2 5/2006 Gaudout et al. .............. 424/765 7,179,841 B2 2/2007 Zielinski et al. .. ... 514,474 (72) Inventors: Jan Zielinski, Vista, CA (US); Thomas 2003/0069302 A1 4/2003 Zielinski ........ ... 514,452 Russell Moon, Dallas, TX (US); 2004/0037860 A1 2/2004 Maillon ...... ... 424/401 Edward P. Allen, Dallas, TX (US) 2004/0091589 A1 5, 2004 Roy et al. ... 426,265 s s 2004/0224004 A1 1 1/2004 Zielinski ..... ... 424/442 2005/0032882 A1 2/2005 Chen ............................. 514,456 (73) Assignee: Perio Sciences, LLC, Dallas, TX (US) 2005, 0137205 A1 6, 2005 Van Breen ..... 514,252.12 2005. O154054 A1 7/2005 Zielinski et al. ............. 514,474 (*) Notice: Subject to any disclaimer, the term of this 2005/0271692 Al 12/2005 Gervasio-Nugent patent is extended or adjusted under 35 et al. ............................. 424/401 2006/0173065 A1 8/2006 BeZwada ...................... 514,419 U.S.C. 154(b) by 19 days. 2006/O193790 A1 8/2006 Doyle et al.
    [Show full text]
  • Supplementary Materials Evodiamine Inhibits Both Stem Cell and Non-Stem
    Supplementary materials Evodiamine inhibits both stem cell and non-stem-cell populations in human cancer cells by targeting heat shock protein 70 Seung Yeob Hyun, Huong Thuy Le, Hye-Young Min, Honglan Pei, Yijae Lim, Injae Song, Yen T. K. Nguyen, Suckchang Hong, Byung Woo Han, Ho-Young Lee - 1 - Table S1. Short tandem repeat (STR) DNA profiles for human cancer cell lines used in this study. MDA-MB-231 Marker H1299 H460 A549 HCT116 (MDA231) Amelogenin XX XY XY XX XX D8S1179 10, 13 12 13, 14 10, 14, 15 13 D21S11 32.2 30 29 29, 30 30, 33.2 D7S820 10 9, 12 8, 11 11, 12 8 CSF1PO 12 11, 12 10, 12 7, 10 12, 13 D3S1358 17 15, 18 16 12, 16, 17 16 TH01 6, 9.3 9.3 8, 9.3 8, 9 7, 9.3 D13S317 12 13 11 10, 12 13 D16S539 12, 13 9 11, 12 11, 13 12 D2S1338 23, 24 17, 25 24 16 21 D19S433 14 14 13 11, 12 11, 14 vWA 16, 18 17 14 17, 22 15 TPOX 8 8 8, 11 8, 9 8, 9 D18S51 16 13, 15 14, 17 15, 17 11, 16 D5S818 11 9, 10 11 10, 11 12 FGA 20 21, 23 23 18, 23 22, 23 - 2 - Table S2. Antibodies used in this study. Catalogue Target Vendor Clone Dilution ratio Application1) Number 1:1000 (WB) ADI-SPA- 1:50 (IHC) HSP70 Enzo C92F3A-5 WB, IHC, IF, IP 810-F 1:50 (IF) 1 :1000 (IP) ADI-SPA- HSP90 Enzo 9D2 1:1000 WB 840-F 1:1000 (WB) Oct4 Abcam ab19857 WB, IF 1:100 (IF) Nanog Cell Signaling 4903S D73G4 1:1000 WB Sox2 Abcam ab97959 1:1000 WB ADI-SRA- Hop Enzo DS14F5 1:1000 WB 1500-F HIF-1α BD 610958 54/HIF-1α 1:1000 WB pAkt (S473) Cell Signaling 4060S D9E 1:1000 WB Akt Cell Signaling 9272S 1:1000 WB pMEK Cell Signaling 9121S 1:1000 WB (S217/221) MEK Cell Signaling 9122S 1:1000
    [Show full text]
  • Comparative Studies of Corrosion Inhibitive Properties of Benzofuran
    ISSN (Online) 2456-1290 International Journal of Engineering Research in Mechanical and Civil Engineering (IJERMCE) Vol 2, Issue 11,November 2017 Comparative studies of Corrosion Inhibitive Properties of Benzofuran-2-carboxylic acid & Amla Leaves Extract On Mild Steel in Acid Media [1] Abhishek Kumar, [2] Ankit Aggarwal, [3] Ashutosh Krishna Piyush, [4] Abhishek Kumar, [5] Aatiq ShafiqDar, [6] Angel Roy, [7] Dr Hari Krishna S [1][2][3][6] 1st Year Department Of Computer Science & Engineering, Sri SaiRam College Of Engineering, Bangalore, [4] 1st Year Department of Electrical & Electronics, Sri SaiRam College Of Engineering, Bangalore [5] 1st Year Department Of Mechanical Engineering, Sri SaiRam College Of Engineering, Bangalore [7] Assistant Professor, Department Of Chemistry, Sri SaiRam College Of Engineering, Bangalore Abstract:- The effects of Benzofuran-2-carboxylic acid (BF) & Amla (Emblica officinal is) leaves aqueous extract as a corrosion inhibitor, behaviour of mild steel has been investigated in hydrochloric acid solutions containing Experiments were performed by weight loss method for different time intervals and at room temperature. The inhibition efficiency of Benzofuran-2-carboxylic acid was found to increase with inhibitor concentration and also in the presence of sodium bromide and sodium iodide. Inhibition efficiency was found to increase with increasing concentration of inhibitor (0.2 g /l to 10 g/l) for 6 hours at room temperature. The maximum inhibition efficiency of Emblica officinal is leaving 87 % in 1 N Hydrochloric acid. From the comparative studies, it was investigated that the corrosion inhibition efficiency of Emblica officinal is leaving as aqueous extract is approximately equal to that of Benzofuran-2-carboxylic acid in hydrochloric acid.
    [Show full text]
  • USP Statement on Validation of DNA Test Methods for Regulating the Quality of Herbal Supplements
    USP Statement on Validation of DNA Test Methods for Regulating the Quality of Herbal Supplements U.S. PHARMACOPEIAL CONVENTION The United States Pharmacopeial Convention Urges Scientific Validation of DNA Test Methods for Regulating the Quality of Herbal Supplements (Rockville, MD – April 16, 2015) – In response to an agreement announced between the New York State Attorney General (NYAG) and GNC Holdings, Inc. (GNC) the United States Pharmacopeial Convention (USP), an independent, science based, standards setting organization and publishers of the United States Pharmacopeia-National Formulary (USP-NF), an official compendia of quality standards for dietary supplements sold in the U.S., issued the following statement: Statement by Gabriel Giancaspro, PhD – Vice President –Foods, Dietary Supplement and Herbal Medicines United States Pharmacopeial Convention (USP) “As a science-based standards-setting organization, the United States Pharmacopeial Convention (USP) has a keen interest in adopting emerging technologies to ensure the test methods and quality standards included in the United States Pharmacopeia-National Formulary (USP-NF) are current and reflect the state of the industry. DNA testing including DNA Barcoding, is just one example of a technology that has been recently added to the USP-NF. As of December 2014, DNA-based identification methods are included in the official USP chapter <563> Identification of Articles of Botanical Origin. However, this method is not yet referenced in a USP-NF monograph (quality standard) for a specific ingredient or product. That is because USP quality standards are specific for each ingredient, product and dosage form and the standards we develop include only those test methods that have been scientifically validated and shown to be fit for purpose.
    [Show full text]
  • Mechanisms of Toxic Action of the Flavonoid Quercetin and Its Phase II Metabolites
    Mechanisms of toxic action of the flavonoid quercetin and its phase II metabolites Hester van der Woude Promotor: Prof. Dr. Ir. I.M.C.M. Rietjens Hoogleraar in de Toxicologie Wageningen Universiteit Co-promotor: Dr. G.M. Alink Universitair Hoofddocent, Sectie Toxicologie Wageningen Universiteit. Promotiecommissie: Prof. Dr. A. Bast Universiteit Maastricht Dr. Ir. P.C.H. Hollman RIKILT Instituut voor Voedselveiligheid, Wageningen Prof. Dr. Ir. F.J. Kok Wageningen Universiteit Prof. Dr. T. Walle Medical University of South Carolina, Charleston, SC, USA Dit onderzoek is uitgevoerd binnen de onderzoekschool VLAG Mechanisms of toxic action of the flavonoid quercetin and its phase II metabolites Hester van der Woude Proefschrift ter verkrijging van de graad van doctor op gezag van de rector magnificus van Wageningen Universiteit, Prof. Dr. M.J. Kropff, in het openbaar te verdedigen op vrijdag 7 april 2006 des namiddags te half twee in de Aula Title Mechanisms of toxic action of the flavonoid quercetin and its phase II metabolites Author Hester van der Woude Thesis Wageningen University, Wageningen, the Netherlands (2006) with abstract, with references, with summary in Dutch. ISBN 90-8504-349-2 Abstract During and after absorption in the intestine, quercetin is extensively metabolised by the phase II biotransformation system. Because the biological activity of flavonoids is dependent on the number and position of free hydroxyl groups, a first objective of this thesis was to investigate the consequences of phase II metabolism of quercetin for its biological activity. For this purpose, a set of analysis methods comprising HPLC-DAD, LC-MS and 1H NMR proved to be a useful tool in the identification of the phase II metabolite pattern of quercetin in various biological systems.
    [Show full text]
  • In Vitro Bioaccessibility, Human Gut Microbiota Metabolites and Hepatoprotective Potential of Chebulic Ellagitannins: a Case of Padma Hepatenr Formulation
    Article In Vitro Bioaccessibility, Human Gut Microbiota Metabolites and Hepatoprotective Potential of Chebulic Ellagitannins: A Case of Padma Hepatenr Formulation Daniil N. Olennikov 1,*, Nina I. Kashchenko 1,: and Nadezhda K. Chirikova 2,: Received: 28 August 2015 ; Accepted: 30 September 2015 ; Published: 13 October 2015 1 Laboratory of Medical and Biological Research, Institute of General and Experimental Biology, Siberian Division, Russian Academy of Science, Sakh’yanovoy Street 6, Ulan-Ude 670-047, Russia; [email protected] 2 Department of Biochemistry and Biotechnology, North-Eastern Federal University, 58 Belinsky Street, Yakutsk 677-027, Russian; [email protected] * Correspondence: [email protected]; Tel.: +7-9021-600-627; Fax: +7-3012-434-243 : These authors contributed equally to this work. Abstract: Chebulic ellagitannins (ChET) are plant-derived polyphenols containing chebulic acid subunits, possessing a wide spectrum of biological activities that might contribute to health benefits in humans. The herbal formulation Padma Hepaten containing ChETs as the main phenolics, is used as a hepatoprotective remedy. In the present study, an in vitro dynamic model simulating gastrointestinal digestion, including dialysability, was applied to estimate the bioaccessibility of the main phenolics of Padma Hepaten. Results indicated that phenolic release was mainly achieved during the gastric phase (recovery 59.38%–97.04%), with a slight further release during intestinal digestion. Dialysis experiments showed that dialysable phenolics were 64.11% and 22.93%–26.05% of their native concentrations, respectively, for gallic acid/simple gallate esters and ellagitanins/ellagic acid, in contrast to 20.67% and 28.37%–55.35% for the same groups in the non-dialyzed part of the intestinal media.
    [Show full text]
  • Treatment Repurposing for Inflammatory Bowel Disease Using Literature-Related Discovery and Innovation Kostoff RN, Briggs MB, Shores DR
    ISSN 1007-9327 (print) ISSN 2219-2840 (online) World Journal of Gastroenterology World J Gastroenterol 2020 September 7; 26(33): 4889-5059 Published by Baishideng Publishing Group Inc World Journal of W J G Gastroenterology Contents Weekly Volume 26 Number 33 September 7, 2020 FRONTIER 4889 Treatment repurposing for inflammatory bowel disease using literature-related discovery and innovation Kostoff RN, Briggs MB, Shores DR REVIEW 4900 Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells Polidoro MA, Mikulak J, Cazzetta V, Lleo A, Mavilio D, Torzilli G, Donadon M MINIREVIEWS 4919 Exploring the food-gut axis in immunotherapy response of cancer patients Russo E, Nannini G, Dinu M, Pagliai G, Sofi F, Amedei A ORIGINAL ARTICLE Basic Study 4933 Tumor necrosis factor alpha receptor 1 deficiency in hepatocytes does not protect from non-alcoholic steatohepatitis, but attenuates insulin resistance in mice Bluemel S, Wang Y, Lee S, Schnabl B 4945 Resveratrol alleviates intestinal mucosal barrier dysfunction in dextran sulfate sodium-induced colitis mice by enhancing autophagy Pan HH, Zhou XX, Ma YY, Pan WS, Zhao F, Yu MS, Liu JQ Retrospective Study 4960 Effects of denosumab treatment in chronic liver disease patients with osteoporosis Saeki C, Saito M, Oikawa T, Nakano M, Torisu Y, Saruta M, Tsubota A 4972 Bowel function and quality of life after minimally invasive colectomy with D3 lymphadenectomy for right- sided colon adenocarcinoma Lee KM, Baek SJ, Kwak JM, Kim J, Kim SH 4983 Acute liver failure and death
    [Show full text]
  • Note: the Letters 'F' and 'T' Following the Locators Refers to Figures and Tables
    Index Note: The letters ‘f’ and ‘t’ following the locators refers to figures and tables cited in the text. A Acyl-lipid desaturas, 455 AA, see Arachidonic acid (AA) Adenophostin A, 71, 72t aa, see Amino acid (aa) Adenosine 5-diphosphoribose, 65, 789 AACOCF3, see Arachidonyl trifluoromethyl Adlea, 651 ketone (AACOCF3) ADP, 4t, 10, 155, 597, 598f, 599, 602, 669, α1A-adrenoceptor antagonist prazosin, 711t, 814–815, 890 553 ADPKD, see Autosomal dominant polycystic aa 723–928 fragment, 19 kidney disease (ADPKD) aa 839–873 fragment, 17, 19 ADPKD-causing mutations Aβ, see Amyloid β-peptide (Aβ) PKD1 ABC protein, see ATP-binding cassette protein L4224P, 17 (ABC transporter) R4227X, 17 Abeele, F. V., 715 TRPP2 Abbott Laboratories, 645 E837X, 17 ACA, see N-(p-amylcinnamoyl)anthranilic R742X, 17 acid (ACA) R807X, 17 Acetaldehyde, 68t, 69 R872X, 17 Acetic acid-induced nociceptive response, ADPR, see ADP-ribose (ADPR) 50 ADP-ribose (ADPR), 99, 112–113, 113f, Acetylcholine-secreting sympathetic neuron, 380–382, 464, 534–536, 535f, 179 537f, 538, 711t, 712–713, Acetylsalicylic acid, 49t, 55 717, 770, 784, 789, 816–820, Acrolein, 67t, 69, 867, 971–972 885 Acrosome reaction, 125, 130, 301, 325, β-Adrenergic agonists, 740 578, 881–882, 885, 888–889, α2 Adrenoreceptor, 49t, 55, 188 891–895 Adult polycystic kidney disease (ADPKD), Actinopterigy, 223 1023 Activation gate, 485–486 Aframomum daniellii (aframodial), 46t, 52 Leu681, amino acid residue, 485–486 Aframomum melegueta (Melegueta pepper), Tyr671, ion pathway, 486 45t, 51, 70 Acute myeloid leukaemia and myelodysplastic Agelenopsis aperta (American funnel web syndrome (AML/MDS), 949 spider), 48t, 54 Acylated phloroglucinol hyperforin, 71 Agonist-dependent vasorelaxation, 378 Acylation, 96 Ahern, G.
    [Show full text]
  • Toxicology in Antiquity
    TOXICOLOGY IN ANTIQUITY Other published books in the History of Toxicology and Environmental Health series Wexler, History of Toxicology and Environmental Health: Toxicology in Antiquity, Volume I, May 2014, 978-0-12-800045-8 Wexler, History of Toxicology and Environmental Health: Toxicology in Antiquity, Volume II, September 2014, 978-0-12-801506-3 Wexler, Toxicology in the Middle Ages and Renaissance, March 2017, 978-0-12-809554-6 Bobst, History of Risk Assessment in Toxicology, October 2017, 978-0-12-809532-4 Balls, et al., The History of Alternative Test Methods in Toxicology, October 2018, 978-0-12-813697-3 TOXICOLOGY IN ANTIQUITY SECOND EDITION Edited by PHILIP WEXLER Retired, National Library of Medicine’s (NLM) Toxicology and Environmental Health Information Program, Bethesda, MD, USA Academic Press is an imprint of Elsevier 125 London Wall, London EC2Y 5AS, United Kingdom 525 B Street, Suite 1650, San Diego, CA 92101, United States 50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom Copyright r 2019 Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher’s permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions. This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]